

November 2, 2022

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, DC 20549-3720

Attention: Jason Drory

Re: **Aadi Bioscience, Inc.**  
**Registration Statement on Form S-3**  
**File No. 333-268021**

**Acceleration Request**

**Requested Date: November 4, 2022**

**Requested Time: 4:00 P.M. Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aadi Bioscience, Inc. (the “**Company**”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-268021) (the “**Registration Statement**”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Dan Koeppen at (858) 350-2393 or via email at [dkoeppen@wsgr.com](mailto:dkoeppen@wsgr.com).

*[Signature page follows]*

Sincerely,

AADI BIOSCIENCE, INC.

/s/ Neil Desai

Neil Desai

*President and Chief Executive Officer*

cc: Dan Koeppen, Wilson Sonsini Goodrich & Rosati, P.C.  
Robert L. Wernli, Jr., Wilson Sonsini Goodrich & Rosati, P.C.  
David G. Sharon, Wilson Sonsini Goodrich & Rosati, P.C.